CAMELLINO, DARIO
 Distribuzione geografica
Continente #
EU - Europa 3.391
AS - Asia 21
SA - Sud America 3
NA - Nord America 1
Totale 3.416
Nazione #
IT - Italia 3.391
CN - Cina 18
AR - Argentina 2
VN - Vietnam 2
BR - Brasile 1
SG - Singapore 1
US - Stati Uniti d'America 1
Totale 3.416
Città #
Genova 1.384
Genoa 1.325
Vado Ligure 391
Rapallo 282
Bordighera 9
Beijing 4
Comodoro Rivadavia 1
Ha Long 1
Hải Dương 1
Necochea 1
New York 1
Rio de Janeiro 1
Singapore 1
Totale 3.402
Nome #
A Positron Emission Tomography/Computed Tomography (PET/CT) Evaluation of Asymptomatic Abdominal Aortic Aneurysms: Another Point of View. 189
Cardiovascular diseases in patients with rheumatoid arthritis: comment on the article by Koivuniemi et al. 165
Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography 162
Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition 148
Polymyalgia rheumatica or lymphoma recurrence? Positron emission tomography/computed tomography is a specific imaging technique that helps differential diagnosis 144
Seronegative spondyloarthropathies: what radiologists should know 133
Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain 132
High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography 123
Ankylosis of the wrist bones in patients with rheumatoid arthritis: a study with extremity-dedicated MRI 121
11. Steroid schedules in PMR 113
Systemic vascular inflammation in abdominal aortic aneurysm patients: a contrast-enhanced PET/CT study 112
2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative 110
Methotrexate treatment of polymyalgia rheumatica/giant cell arteritis-associated large vessel vasculitis. 106
FRI0480 CHANGES IN CIRCULATING SCTLA-4 FOLLOWING ZOLEDRONIC ACID INFUSION 105
Seronegative spondyloarthritis and Darier's disease: more than a casual association? 100
The multifaceted pathogenesis of polymyalgia rheumatica/giant cell arteritis. 92
IMAGING AND SEROLOGICAL PROFILING OF PATIENTS WITH POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS 91
Cardiac and aortic involvement in patients with polymyalgia rheumatica: a study with echocardiography and FDG-PET/CT 90
Imaging in arthritis: quantifying effects of therapeutic intervention using MRI and molecular imaging. 84
[Polymyalgia rheumatica and aortic involvement]. 83
Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts (Arthritis Res Ther (2019) 21:275 DOI: 10.1186/s13075-019-2021-9) 81
Clinical and FDG-PET/CT correlates in patients with polymyalgia rheumatica 70
Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption 69
Do statins decrease vascular inflammation in patients at risk for large-vessel vasculitis? A retrospective observational study with FDG-PET/CT in polymyalgia rheumatica, giant cell arteritis and fever of unknown origin 57
Involvement of different knee structures reveleated by PET-CT in polymyalgia rheumatica 56
AB0354 FDG-PET-DETECTED LARGE VESSEL VASCULITIS DOES NOT PREDICT DISEASE OUTCOME IN PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA 51
AB1289 HIGHER BASELINE FDG JOINT UPTAKE AT PET/CT IS ASSOCIATED WITH A HIGHER REMISSION RATE IN POLYMYALGIA RHEUMATICA: A RETROSPECTIVE 3-YEAR OBSERVATIONAL STUDY 47
Management of giant cell arteritis among general practitioners from Genoa, Italy: a web-based survey. 44
Extrusion of the medial meniscus in knee osteoarthritis assessed with a rotating clino-orthostatic permanent-magnet MRI scanner 44
Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides 41
A seasonal pattern in the onset of polymyalgia rheumatica and giant cell arteritis? A systematic review and meta-analysis 40
Seasonal onset of polymyalgia rheumatica: correlations with the pattern of clinical presentation, disease severity and outcome in 383 patients from a single centre. 39
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC 35
Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review 34
Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: A systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica 32
Are the new ACR/EULAR criteria the ultimate answer for polymyalgia rheumatica classification? 27
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: Executive summary 26
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis 25
[Polymyalgia rheumatica: diagnostic and therapeutic issues of an apparently straightforward disease.] 24
The provisional OMERACT ultrasonography score for giant cell arteritis 24
From polymyalgia arteritica to arteritis polymyalgica: redefining the GCA-PMR spectrum through advanced MRI insights 22
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica 21
Soluble Co‐Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case‐Control Study 20
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 18
Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis? 18
Update on treatment of polymyalgia rheumatica 17
Should 18F-FDG-PET imaging be used in the diagnosis of GCA? 15
Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data 14
Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica 13
Large vessel vasculitis: Which imaging method? 12
New insights into the role of imaging in polymyalgia rheumatica 11
Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica 11
Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force 11
Large vessel vasculitis: Is it more common than usually assumed? 10
Reply to: What could a new disease activity score for polymyalgia rheumatica do better? 10
AB0683 Treatment with statins in patients studied by fdg-pet/ct for possible large vessel vasculitis is associated with a low vascular score 9
THU0454 Increased fdg uptake of the muscles in polymyalgia rheumatica (PMR) 3
SAT0215 Twelve Year Follow-Up on Progression of Nailfold Microangiopathy Detected through Transition between Different Capillaroscopic Patterns of Microvascular Damage in Systemic Sclerosis 3
FRI0033 TNFalpha Production In Cultured Human Macrophages after CTLA4-IG (abatacept) In Vitro Treatment 2
Totale 3.509
Categoria #
all - tutte 13.084
article - articoli 12.311
book - libri 0
conference - conferenze 443
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.838


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021156 0 0 0 16 12 30 10 12 19 21 19 17
2021/2022286 5 18 12 33 13 26 17 69 21 27 5 40
2022/2023332 28 61 3 24 40 47 3 18 42 5 61 0
2023/2024234 3 40 4 32 18 27 13 16 6 5 13 57
2024/2025925 21 115 32 65 105 95 66 160 14 30 88 134
2025/2026591 215 52 189 135 0 0 0 0 0 0 0 0
Totale 3.509